# US 2014/0212382 A1 · Purine monophosphate prodrugs for treatment of viral infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0212382 A1
- Document ID: US20140212382A1
- Status: Published application
- Kind: A1
- Application number: 14/117,815
- Filed: 2012-05-16
- Published: 2014-07-31
- Earliest claimed: 2011-05-19
- Assignees: Emory University; RFS Pharma, LLC
- Inventors: Raymond F. Schinazi; Jong Hyun Cho; Longhu Zhou; Hongwang Zhang; Ugo Pradere; Steven J. Coats
- Web page: https://patentgrep.com/patent/US20140212382A1

## CPC

- A61P 31/12: Antivirals
- C07F 9/65586: {at least one of the hetero rings does not contain nitrogen as ring hetero atom}
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 473/16: two nitrogen atoms
- C07F 9/65742: {non-condensed with carbocyclic rings or heterocyclic rings or ring systems}
- C07H 19/20: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H 19/207: the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
- C07H 19/213: containing cyclic phosphate
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present invention is directed to compounds, compositions and methods for treating or preventing viral infections using nucleoside analog monophosphate prodrugs. More specifically, HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever in human patients or other animal hosts. The compounds are certain 2,6-diamino 2-C-methyl purine nucleoside monophosphate prodrugs and modified prodrug analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever. This invention teaches how to modify the metabolic pathway of 2,6-diamino 2′-C-methyl purine and deliver nucleotide triphosphate(s) to polymerases at heretofore unobtainable therapeutically-relevant concentrations.

## Claims

### Claim 1

A compound of Formula (A) or a compound of Formula (B):
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
when chirality exists at the phosphorous center it may be wholly or partially Rp or Sp or any mixture thereof
R1 is OH or F;
Y is O or S;
R24 is selected from OR15,
and fatty alcohols,
wherein R15, R17, and R18 are as defined below;
R2 and R3, when administered in vivo, are capable of providing the nucleoside monophosphate or thiomonophosphate that is either partially or fully resistant to 6-NH2 deamination in a biological system and are independently selected from the group consisting of:
(a) OR15 where R15 selected from H, Li, Na, K, phenyl and pyridinyl; Phenyl and pyridinyl are substituted with one to three substituents independently selected from the group consisting of (CH2)0-6CO2R16 and (CH2)0-6CON(R16)2;
R16 is independently H, C1-20 alkyl, the carbon chain derived from a fatty alcohol or C1-20 alkyl substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C3-10 cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1-5 alkyl, or C1-5 alkyl substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C3-10 cycloalkyl, or cycloalkyl;
(c) the ester of an L-amino acid
where R17 is restricted to those occurring in natural L-amino acids, and R18 is H, C1-20 alkyl, the carbon chain derived from a fatty alcohol or C1-20 alkyl substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C3-10 cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1-5 alkyl, or C1-5 alkyl substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C3-10 cycloalkyl, or cycloalkyl;
(d) R2 and R3 together to form a ring
where R19 is H, C1-20 alkyl, C1-20 alkenyl, the carbon chain derived from a fatty alcohol or C1-20 alkyl substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C3-10 cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1-5 alkyl, or C1-5 alkyl substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C3-10 cycloalkyl, or cycloalkyl; and
(e) R2 and R3 together to form a ring selected from
where R20 is O or NH and
R21 is selected from H, C1-20 alkyl, C1-20 alkenyl, the carbon chain derived from a fatty acid, and C1-20 alkyl substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C3-10 cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C1-5 alkyl, or C1-5 alkyl substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C3-10 cycloalkyl, or cycloalkyl.

### Claim 2 (depends on 1)

The compounds of claim 1, wherein the compounds are in the β-D configuration.

### Claim 3 (depends on 1)

The compounds of claim 1, wherein the compounds are converted in a biological system to mixture C or D of 6-NH2 and 6-OH purine triphosphates.

### Claim 4 (depends on 1)

The compounds of claim 1, wherein the compounds are converted in a biological system to therapeutically-relevant concentrations of 2,6-diamino 2′-C-methyl purine triphosphate, E or 2,6-diamino 2′-C-methyl 2′-deoxy 2′-fluoro purine triphosphate, F.

### Claim 5 (depends on 1)

A compound of claim 1 of the formula:
wherein R1 is as defined in claim 1, and R4 is C1-6 alkyl or a carbon chain derived from a fatty alcohol.

### Claim 6 (depends on 5)

The compound of claim 5, wherein the values of R1, R4, and R5 are selected as follows:
R1
R4
R5
OH
Me
Me
F
Me
Me
OH
Et
Et
F
Et
Et
OH
i-Pr
i-Pr
F
i-Pr
i-Pr
OH
oleyl
oleyl
F
oleyl
oleyl

### Claim 7 (depends on 1)

A compound of claim 1 of the formula:
wherein R1 is as defined in claim 1, R6 is H or an alkali metal, and R7 a carbon chain derived from a fatty alcohol.

### Claim 8 (depends on 7)

A compound of claim 7, wherein the values for R1, R6, and R7 are as provided below:
R1
R6
R7
OH
Na+
linoleyl
F
Na
linoleyl
OH
K
linoleyl
F
K
linoleyl
OH
Na
oleyl
F
Na
oleyl
OH
K
oleyl
F
K
oleyl

### Claim 9 (depends on 1)

A compound of claim 1 of the formula:
wherein R1 is as defined in claim 1, and R8 is a fatty acid radical.

### Claim 10 (depends on 9)

A compound of claim 9, wherein the values for R1 and R8 are as provided below:
R1
R8
OH
linoleyl
F
linoleyl
OH
oleyl
F
oleyl

### Claim 11 (depends on 1)

A compound of claim 1 of the formulas:
wherein R1 is as defined in claim 1, and R9 is O or NH, and R10 is a C1-6 alkyl or a carbon chain derived from a fatty alcohol.

### Claim 12 (depends on 11)

A compound of claim 11, wherein the values for R1, R9, and R10 are as provided below:
R1
R9
R10
OH
O
Me
F
O
Me
OH
NH
Me
F
NH
Me
OH
O
Et
F
O
Et
OH
NH
Et
F
NH
Et
OH
O
i-Pr
F
O
i-Pr
OH
NH
i-Pr
F
NH
i-Pr

### Claim 13 (depends on 1)

A compound of claim 1 having the formulas:
wherein R1 is as defined in claim 1, and R11 is a C1-6 alkyl or a carbon chain derived from a fatty alcohol.

### Claim 14 (depends on 13)

A compound of claim 13, wherein the values of R1 and R11 are as provided below:
R1
R11
OH
Me
F
Me
OH
Et
F
Et
OH
i-Pr
F
i-Pr

### Claim 15 (depends on 1)

A compound of claim 1 of the formulas:
wherein R1 is as defined in claim 1, and R12 and R13 are, independently, O or NH.

### Claim 16 (depends on 15)

A compound of claim 15, wherein the values of R1, R12, and R13 are as provided below:
R1
R12
R13
OH
O
O
F
O
O
OH
O
NH
F
O
NH
OH
NH
NH
F
NH
NH

### Claim 17 (depends on 1)

A compound of claim 1 having the formula:
wherein R1 is as defined in claim 1, R4 is C1-6 alkyl or a carbon chain derived from a fatty alcohol, and R12 is O or NH.

### Claim 18 (depends on 17)

A compound of claim 17, wherein the values of R1, R4, and R12 are as provided below:
R1
R4
R12
OH
Me
O
F
Me
O
OH
Et
O
F
Et
O
OH
i-Pr
O
F
i-Pr
O
OH
oleyl
O
OH
Me
NH
F
Me
NH
OH
Et
NH
F
Et
NH
OH
i-Pr
NH
F
i-Pr
NH
OH
oleyl
NH
F
oleyl
NH

### Claim 19 (depends on 1)

A compound of claim 1 of the formula:
wherein
and R11, R7 and R13 are as defined above.

### Claim 20 (depends on 1)

A process for preparing compounds of claim 1 wherein the phosphorous-5′-oxygen bond is formed by reaction with a reagent of general formulas G or H:
wherein:
the chirality at the phosphorous center of formulas G or H can be wholly or partially Rp or Sp or any mixture thereof,
Y, R2 and R3 are as defined above, and
R22 is, independently, H, C1-20 alkyl, CF3, aryl, heteroaryl, substituted aryl, or substituted heteroaryl, or C1-20 alkyl substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, chloro, fluoro, aryl, such as phenyl, heteroaryl, substituted aryl, or substituted heteroaryl.

### Claim at position 21

21-32. (canceled)

### Claim 33 (depends on 1)

A method for treating a host infected with Flaviviridae family of viruses, or for reducing the biological activity of an infection with Flaviviridae family of viruses, comprising administering an effective amount of a compound of claim 1 to a patient in need of treatment thereof.

### Claim at position 23

34-35. (canceled)

### Claim 36 (depends on 33)

The method of claim 33, wherein the compound is administered in combination with another anti-Flaviviridae virus agent.

### Claim 37

(canceled)

### Claim 38 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically-acceptable carrier.

### Claim 39 (depends on 1, 34)

The method of claim 34, for treating a host infected with wherein the Flaviviridae virus is Norovirus or Saporovirus, comprising administering an effective amount of a compound of claim 1 to a patient in need of treatment thereof.

### Claim at position 28

40-43. (canceled)

### Claim 44 (depends on 38)

The pharmaceutical composition of claim 38, further comprising a second antiviral agent.

### Claim 45 (depends on 44)

The pharmaceutical composition of claim 44, wherein the second antiviral agent is selected from the group consisting of an interferon, ribavirin, an NS3 protease inhibitor, an NS5A inhibitor, a non-nucleoside polymerase inhibitor, a helicase inhibitor, a polymerase inhibitor, a nucleotide or nucleoside analogue, an inhibitor of IRES dependent translation, and combinations thereof.
